Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
Company research
Rohto Pharmaceutical Co., Ltd. (OTC: RPHCF) is a Japan-based multinational company founded in 1899 and headquartered in Osaka, Japan, that manufactures and markets pharmaceuticals, cosmetics, and functional foods across more than 110 countries. The company operates through key segments including eye care, skincare, oral medicine, and health food, with notable consumer brands such as Hada Labo, Melano CC, and Obagi, while also commanding approximately 40% of Japan's OTC eye drops market. Beyond its core businesses, Rohto has diversified into emerging fields such as regenerative medicine, medical ophthalmic drugs, and agri-farms, guided by its Management Vision 2030 strategy. With over 9,000 full-time employees and a market capitalization of approximately USD 3.4 billion, Rohto continues to expand its global footprint, with overseas sales accounting for roughly 40% of total revenues.
Research reports
JCR affirms Rohto’s long‑term issuer rating at A+ with a Stable outlook, emphasizing its leading brands in OTC eye drops and skincare, strong product development and marketing capabilities, growing overseas sales (around half of revenue), and very solid balance sheet with a high equity ratio and a substantively debt‑free position. It expects continued sales and operating income growth led by Asia, positive contribution from the Eu Yan Sang acquisition, and expansion of internal medicine, food, regenerative medicine, and medical ophthalmology businesses, while maintaining operating margins near current levels and containing financial risk.
Asset Value Investors Limited · April 30, 2026Awakening ROHTO (2026 Presentation)AVI’s activist research presentation argues that Rohto is significantly undervalued, estimating intrinsic value above ¥6,000 per share versus a current stock price around ¥2,388 and projecting 200%+ upside if the company strengthens IR, clarifies business focus, and improves capital allocation. It identifies four core levers—accelerating growth and profitability in skincare (including brand consolidation and drugstore collaborations), realizing synergies and disciplined PMI from the Eu Yan Sang acquisition, rigorously reassessing regenerative medicine and medical businesses in light of cost of capital, and ending founder‑led governance by dismissing Chairman Kunio Yamada—to unlock value and close the valuation gap versus peers.